Anna Kreutzman

1.3k total citations
42 papers, 821 citations indexed

About

Anna Kreutzman is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Anna Kreutzman has authored 42 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 23 papers in Immunology and 19 papers in Genetics. Recurrent topics in Anna Kreutzman's work include Chronic Myeloid Leukemia Treatments (21 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Immune Cell Function and Interaction (15 papers). Anna Kreutzman is often cited by papers focused on Chronic Myeloid Leukemia Treatments (21 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Immune Cell Function and Interaction (15 papers). Anna Kreutzman collaborates with scholars based in Finland, Sweden and Germany. Anna Kreutzman's co-authors include Satu Mustjoki, Kimmo Porkka, Leif Stenke, Marja Ekblom, Ruth Seggewiss, Mette Ilander, Vesa Juvonen, Jukka Vakkila, Veli Kairisto and Teresa Pinho e Melo and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Blood.

In The Last Decade

Anna Kreutzman

40 papers receiving 817 citations

Peers

Countries citing papers authored by Anna Kreutzman

Since Specialization

Citations

This map shows the geographic impact of Anna Kreutzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Kreutzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Kreutzman more than expected).

Fields of papers citing papers by Anna Kreutzman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Kreutzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Kreutzman. The network helps show where Anna Kreutzman may publish in the future.

Co-authorship network of co-authors of Anna Kreutzman

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Kreutzman. A scholar is included among the top collaborators of Anna Kreutzman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Kreutzman. Anna Kreutzman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study 2024 ·Future Oncology ·Kalle Mattila, Leena Tiainen, (unknown), Anna Kreutzman, (unknown), Kai Kysenius, (unknown), (unknown), (unknown), (unknown), Siru Mäkelä	0
2	Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma 2023 ·Journal of Clinical Investigation ·Jani Huuhtanen, (unknown), Katriina Peltola, Tapio Lönnberg, Virpi Glumoff, Oscar Brück, Olli Dufva, Karita Peltonen, (unknown), Emmi Jokinen, Mette Ilander, Moon Hee Lee, Siru Mäkelä, Marta Nyakas, Bin Li, Micaela Hernberg, Petri Bono, Harri Lähdesmäki, Anna Kreutzman, Satu Mustjoki	60
3	Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma 2023 ·Cancer Research Communications ·Moon Hee Lee, (unknown), Jani Huuhtanen, (unknown), Petrus Järvinen, (unknown), Harry Nísen, Tuomas Mirtti, (unknown), (unknown), Karita Peltonen, Arianna Draghi, Marco Donia, Anna Kreutzman, Satu Mustjoki	6
4	Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation 2023 ·Leukemia ·Jani Huuhtanen, Shady Adnan Awad, (unknown), (unknown), (unknown), Olli Dufva, (unknown), Parashar Dhapola, (unknown), Essi Laajala, Tiina Kasanen, Jay Klievink, Mette Ilander, Taina Jaatinen, Ulla Olsson‐Strömberg, Henrik Hjorth‐Hansen, Andreas Burchert, Göran Karlsson, Anna Kreutzman, Harri Lähdesmäki, Satu Mustjoki	17
5	Evolution and modulation of antigen-specific T cell responses in melanoma patients 2022 ·Nature Communications ·Jani Huuhtanen, Liang Chen, Emmi Jokinen, (unknown), Tapio Lönnberg, Anna Kreutzman, Katriina Peltola, Micaela Hernberg, Chunlin Wang, Cassian Yee, Harri Lähdesmäki, Mark M. Davis, Satu Mustjoki	22
6	Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma 2021 ·Cancer Immunology Research ·Jacopo Chiaro, (unknown), Thomas Whalley, Cristian Capasso, Mikaela Grönholm, Sara Feola, Karita Peltonen, Firas Hamdan, Micaela Hernberg, Siru Mäkelä, (unknown), Paul E. Brown, Beatriz Martins, Manlio Fusciello, Erkko Ylösmäki, Dario Greco, Anna Kreutzman, Satu Mustjoki, Barbara Szomolay, Vincenzo Cerullo	25
7	Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS 2021 ·Blood ·Jani Huuhtanen, Oscar Brück, Karita Peltonen, Anna Kreutzman, Olli Dufva, Matti Kankainen, Mette Ilander, Hanna Lähteenmäki, Tiina Kasanen, Jay Klievink, Mika Kontro, Elena J. Orlando, Viviana Cremasco, Joel P. Wagner, Marc R. Pelletier, Harri Lähdesmäki, Catherine Sabatos-Peyton, Mikael L. Rinne, Kimmo Porkka, Satu Mustjoki	1
8	Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform 2021 ·Molecular Therapy — Oncolytics ·Erkko Ylösmäki, (unknown), Manlio Fusciello, Beatriz Martins, (unknown), (unknown), (unknown), Sara Feola, Anna Kreutzman, Tuuli Ranki, Julia Karbach, Tapani Viitala, (unknown), Elke Jäger, Sari Pesonen, Vincenzo Cerullo	37
9	Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients 2020 ·Cancer Immunology Immunotherapy ·(unknown), Micaela Hernberg, Siru Mäkelä, Oscar Brück, (unknown), (unknown), Mette Ilander, Satu Mustjoki, Anna Kreutzman	16
10	Novel Hemizygous IL2RG p.(Pro58Ser) Mutation Impairs IL-2 Receptor Complex Expression on Lymphocytes Causing X-Linked Combined Immunodeficiency 2020 ·Journal of Clinical Immunology ·Elina Tuovinen, Juha Grönholm, Tiina Öhman, Sakari Pöysti, Raine Toivonen, Anna Kreutzman, Kaarina Heiskanen, Luca Trotta, Sanna Toiviainen‐Salo, John M. Routes, James Verbsky, Satu Mustjoki, Janna Saarela, Juha Kere, Markku Varjosalo, Arno Hänninen, Mikko Seppänen	13
11	Immune cell phenotype and functional defects in Netherton syndrome 2018 ·Orphanet Journal of Rare Diseases ·(unknown), Mette Ilander, (unknown), Antti Mäkitie, (unknown), Anna Kreutzman, Paula Klemetti, Satu Mustjoki, Katariina Hannula‐Jouppi, Annamari Ranki	21
12	Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner 2017 ·Clinical Cancer Research ·Anna Kreutzman, (unknown), Ana Marcos‐Jiménez, Mette Ilander, Carlos Cuesta‐Mateos, (unknown), (unknown), Oscar Brück, (unknown), Jani Saarela, (unknown), (unknown), (unknown), Juan Luis Steegmann, Satu Mustjoki, Miguel Vicente‐Manzanares, Cecilia Muñoz‐Calleja	33
13	A high migratory capacity of donor T-cells in response to the lymph node homing receptor CCR7 increases the incidence and severity of GvHD 2017 ·Bone Marrow Transplantation ·(unknown), (unknown), Carlos Cuesta‐Mateos, (unknown), Lorena Vega‐Piris, (unknown), (unknown), Ana Marcos‐Jiménez, Beatriz Somovilla-Crespo, (unknown), (unknown), (unknown), Anna Kreutzman, Cecilia Muñoz‐Calleja	13
14	Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication 2017 ·Bone Marrow Transplantation ·Ana Arteche‐López, Anna Kreutzman, Adrían Alegre, (unknown), Beatriz Aguado, (unknown), M. Espiño, Luisa María Villar, Daniel García Belmonte, Rafael de la Cámara, Cecilia Muñoz‐Calleja	21
15	Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia 2017 ·Journal of Cancer Research and Clinical Oncology ·Hanna Rajala, (unknown), (unknown), Perttu Koskenvesa, Tim H. Brümmendorf, Bjørn Tore Gjertsen, Jeroen J. W. M. Janssen, Kourosh Lotfi, Berit Markevärn, Ulla Olsson‐Strömberg, Leif Stenke, Jesper Stentoft, Johan Richter, Henrik Hjorth‐Hansen, Anna Kreutzman, Satu Mustjoki	19
16	IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia 2014 ·OncoImmunology ·Mette Ilander, Anna Kreutzman, Satu Mustjoki	5
17	Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy 2014 ·PLoS ONE ·Mette Ilander, Anna Kreutzman, Peter Rohoň, Teresa Pinho e Melo, Edgar Faber, Kimmo Porkka, Jukka Vakkila, Satu Mustjoki	27
18	Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy 2012 ·Leukemia ·Satu Mustjoki, Kaisa Auvinen, Anna Kreutzman, Philippe Rousselot, (unknown), Teresa Pinho e Melo, (unknown), Sampsa Hautaniemi, Stéphane Bouchet, Mathiéu Molimard, Richard Smykla, (unknown), Jukka Vakkila, S Jalkanen, Marko Salmi, Kimmo Porkka	70
19	Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation 2011 ·Leukemia ·Anna Kreutzman, Kristin Ladell, (unknown), Emma Gostick, Marja Ekblom, Leif Stenke, Teresa Pinho e Melo, Hermann Einsele, Kimmo Porkka, David A. Price, Satu Mustjoki, Ruth Seggewiss	72
20	Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile 2011 ·PLoS ONE ·Anna Kreutzman, Peter Rohoň, Edgar Faber, Karel Indrák, Vesa Juvonen, Veli Kairisto, J Voglová, Marjatta Sinisalo, (unknown), Jukka Vakkila, Petteri T. Arstila, Kimmo Porkka, Satu Mustjoki	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact